Impella -Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function

Brief description of study

This study will examine whether using the Impella® device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and the health after a heart procedure compared to the current standard of care. The devices used in this study are already approved for use in patients like yourself by the Food and Drug Administration (FDA). The devices used in this Study include the Impella 2.5®, Impella CP® and Impella CP® with SmartAssist®.


Clinical Study Identifier: s21-00560
ClinicalTrials.gov Identifier: NCT04763200
Principal Investigator: Louai Razzouk.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.